Polyadenosine diphosphate-ribose polymerase inhibition modulates skeletal muscle injury following ischemia reperfusion

Hong T. Hua, Hassan Albadawi, Fateh Entabi, Mark Conrad, Michael C. Stoner, Bryan T. Meriam, Ramses Sroufe, Stuart Houser, Glenn M. LaMuraglia, Michael T. Watkins, Benedict Cosimi, Francis Moore, Thomas Colacchio

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Hypothesis: Polyadenosine diphosphate-ribose polymerase (PARP) has been implicated as a mediator of inflammation and tissue necrosis in murine models of human stroke and myocardial infarction. This study was designed to determine whether PARP modulates skeletal muscle injury and cytokine-growth factor levels during ischemia-reperfusion. Design: Prospective controlled animal study. Setting: Medical school-affiliated university hospital. Interventions: Mice were divided into 2 groups-treated (PJ) and untreated; all mice were subjected to unilateral hind limb tourniquet ischemia followed by 4 or 48 hours of reperfusion. In treated mice, PJ34, an ultrapotent-specific PARP inhibitor was given immediately before ischemia and prior to reperfusion. A group of PARP-1 knockout mice (PARP-/-) were also subjected to hind limb ischemia followed by 48 hours of reperfusion. Main Outcome Measure: After ischemia-reperfusion, muscle was harvested for measurement of edema, viability, cytokine, and vascular endothelial growth factor content. Results: The PJ34-treated mice had increased skeletal muscle viability when compared with the untreated mice after 4 and 48 hours of reperfusion (P<.01). Viability between PARP-/- and PJ34-treated mice were similar at 48 hours of reperfusion (P>.05), and it exceeded that of untreated mice (P<.01). Tissue edema was unaltered by PARP inhibition. Tissue levels of cytokine were only different (P<.05) in PJ34-treated vs untreated mice at 48 hours of reperfusion. Vascular endothelial growth factor levels in PJ34-treated mice were markedly reduced when compared with untreated mice only after 4 hours of reperfusion (P<.01), and in PARP-/- mice (P<.01) at 48 hours of reperfusion. Conclusion: Polyadenosine diphosphate-ribose polymerase modulates skeletal muscle viability, cytokine and vascular endothelial growth factor synthesis during reperfusion. Polyadenosine diphosphate-ribose polymerase inhibition may represent a novel method to modulate skeletal muscle ischemia-reperfusion injury.

Original languageEnglish (US)
Pages (from-to)344-351
Number of pages8
JournalArchives of Surgery
Volume140
Issue number4
DOIs
StatePublished - Apr 1 2005
Externally publishedYes

Fingerprint

Ribose
Diphosphates
Reperfusion Injury
Reperfusion
Skeletal Muscle
Ischemia
Vascular Endothelial Growth Factor A
Cytokines
Edema
Extremities
polyadenosine
Inflammation Mediators
Tourniquets
Medical Schools
Knockout Mice
Intercellular Signaling Peptides and Proteins
Necrosis
Stroke
Myocardial Infarction
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Surgery

Cite this

Polyadenosine diphosphate-ribose polymerase inhibition modulates skeletal muscle injury following ischemia reperfusion. / Hua, Hong T.; Albadawi, Hassan; Entabi, Fateh; Conrad, Mark; Stoner, Michael C.; Meriam, Bryan T.; Sroufe, Ramses; Houser, Stuart; LaMuraglia, Glenn M.; Watkins, Michael T.; Cosimi, Benedict; Moore, Francis; Colacchio, Thomas.

In: Archives of Surgery, Vol. 140, No. 4, 01.04.2005, p. 344-351.

Research output: Contribution to journalArticle

Hua, HT, Albadawi, H, Entabi, F, Conrad, M, Stoner, MC, Meriam, BT, Sroufe, R, Houser, S, LaMuraglia, GM, Watkins, MT, Cosimi, B, Moore, F & Colacchio, T 2005, 'Polyadenosine diphosphate-ribose polymerase inhibition modulates skeletal muscle injury following ischemia reperfusion', Archives of Surgery, vol. 140, no. 4, pp. 344-351. https://doi.org/10.1001/archsurg.140.4.344
Hua, Hong T. ; Albadawi, Hassan ; Entabi, Fateh ; Conrad, Mark ; Stoner, Michael C. ; Meriam, Bryan T. ; Sroufe, Ramses ; Houser, Stuart ; LaMuraglia, Glenn M. ; Watkins, Michael T. ; Cosimi, Benedict ; Moore, Francis ; Colacchio, Thomas. / Polyadenosine diphosphate-ribose polymerase inhibition modulates skeletal muscle injury following ischemia reperfusion. In: Archives of Surgery. 2005 ; Vol. 140, No. 4. pp. 344-351.
@article{e9327b4c01c44a6ebc566aead4d7d1f8,
title = "Polyadenosine diphosphate-ribose polymerase inhibition modulates skeletal muscle injury following ischemia reperfusion",
abstract = "Hypothesis: Polyadenosine diphosphate-ribose polymerase (PARP) has been implicated as a mediator of inflammation and tissue necrosis in murine models of human stroke and myocardial infarction. This study was designed to determine whether PARP modulates skeletal muscle injury and cytokine-growth factor levels during ischemia-reperfusion. Design: Prospective controlled animal study. Setting: Medical school-affiliated university hospital. Interventions: Mice were divided into 2 groups-treated (PJ) and untreated; all mice were subjected to unilateral hind limb tourniquet ischemia followed by 4 or 48 hours of reperfusion. In treated mice, PJ34, an ultrapotent-specific PARP inhibitor was given immediately before ischemia and prior to reperfusion. A group of PARP-1 knockout mice (PARP-/-) were also subjected to hind limb ischemia followed by 48 hours of reperfusion. Main Outcome Measure: After ischemia-reperfusion, muscle was harvested for measurement of edema, viability, cytokine, and vascular endothelial growth factor content. Results: The PJ34-treated mice had increased skeletal muscle viability when compared with the untreated mice after 4 and 48 hours of reperfusion (P<.01). Viability between PARP-/- and PJ34-treated mice were similar at 48 hours of reperfusion (P>.05), and it exceeded that of untreated mice (P<.01). Tissue edema was unaltered by PARP inhibition. Tissue levels of cytokine were only different (P<.05) in PJ34-treated vs untreated mice at 48 hours of reperfusion. Vascular endothelial growth factor levels in PJ34-treated mice were markedly reduced when compared with untreated mice only after 4 hours of reperfusion (P<.01), and in PARP-/- mice (P<.01) at 48 hours of reperfusion. Conclusion: Polyadenosine diphosphate-ribose polymerase modulates skeletal muscle viability, cytokine and vascular endothelial growth factor synthesis during reperfusion. Polyadenosine diphosphate-ribose polymerase inhibition may represent a novel method to modulate skeletal muscle ischemia-reperfusion injury.",
author = "Hua, {Hong T.} and Hassan Albadawi and Fateh Entabi and Mark Conrad and Stoner, {Michael C.} and Meriam, {Bryan T.} and Ramses Sroufe and Stuart Houser and LaMuraglia, {Glenn M.} and Watkins, {Michael T.} and Benedict Cosimi and Francis Moore and Thomas Colacchio",
year = "2005",
month = "4",
day = "1",
doi = "10.1001/archsurg.140.4.344",
language = "English (US)",
volume = "140",
pages = "344--351",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Polyadenosine diphosphate-ribose polymerase inhibition modulates skeletal muscle injury following ischemia reperfusion

AU - Hua, Hong T.

AU - Albadawi, Hassan

AU - Entabi, Fateh

AU - Conrad, Mark

AU - Stoner, Michael C.

AU - Meriam, Bryan T.

AU - Sroufe, Ramses

AU - Houser, Stuart

AU - LaMuraglia, Glenn M.

AU - Watkins, Michael T.

AU - Cosimi, Benedict

AU - Moore, Francis

AU - Colacchio, Thomas

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Hypothesis: Polyadenosine diphosphate-ribose polymerase (PARP) has been implicated as a mediator of inflammation and tissue necrosis in murine models of human stroke and myocardial infarction. This study was designed to determine whether PARP modulates skeletal muscle injury and cytokine-growth factor levels during ischemia-reperfusion. Design: Prospective controlled animal study. Setting: Medical school-affiliated university hospital. Interventions: Mice were divided into 2 groups-treated (PJ) and untreated; all mice were subjected to unilateral hind limb tourniquet ischemia followed by 4 or 48 hours of reperfusion. In treated mice, PJ34, an ultrapotent-specific PARP inhibitor was given immediately before ischemia and prior to reperfusion. A group of PARP-1 knockout mice (PARP-/-) were also subjected to hind limb ischemia followed by 48 hours of reperfusion. Main Outcome Measure: After ischemia-reperfusion, muscle was harvested for measurement of edema, viability, cytokine, and vascular endothelial growth factor content. Results: The PJ34-treated mice had increased skeletal muscle viability when compared with the untreated mice after 4 and 48 hours of reperfusion (P<.01). Viability between PARP-/- and PJ34-treated mice were similar at 48 hours of reperfusion (P>.05), and it exceeded that of untreated mice (P<.01). Tissue edema was unaltered by PARP inhibition. Tissue levels of cytokine were only different (P<.05) in PJ34-treated vs untreated mice at 48 hours of reperfusion. Vascular endothelial growth factor levels in PJ34-treated mice were markedly reduced when compared with untreated mice only after 4 hours of reperfusion (P<.01), and in PARP-/- mice (P<.01) at 48 hours of reperfusion. Conclusion: Polyadenosine diphosphate-ribose polymerase modulates skeletal muscle viability, cytokine and vascular endothelial growth factor synthesis during reperfusion. Polyadenosine diphosphate-ribose polymerase inhibition may represent a novel method to modulate skeletal muscle ischemia-reperfusion injury.

AB - Hypothesis: Polyadenosine diphosphate-ribose polymerase (PARP) has been implicated as a mediator of inflammation and tissue necrosis in murine models of human stroke and myocardial infarction. This study was designed to determine whether PARP modulates skeletal muscle injury and cytokine-growth factor levels during ischemia-reperfusion. Design: Prospective controlled animal study. Setting: Medical school-affiliated university hospital. Interventions: Mice were divided into 2 groups-treated (PJ) and untreated; all mice were subjected to unilateral hind limb tourniquet ischemia followed by 4 or 48 hours of reperfusion. In treated mice, PJ34, an ultrapotent-specific PARP inhibitor was given immediately before ischemia and prior to reperfusion. A group of PARP-1 knockout mice (PARP-/-) were also subjected to hind limb ischemia followed by 48 hours of reperfusion. Main Outcome Measure: After ischemia-reperfusion, muscle was harvested for measurement of edema, viability, cytokine, and vascular endothelial growth factor content. Results: The PJ34-treated mice had increased skeletal muscle viability when compared with the untreated mice after 4 and 48 hours of reperfusion (P<.01). Viability between PARP-/- and PJ34-treated mice were similar at 48 hours of reperfusion (P>.05), and it exceeded that of untreated mice (P<.01). Tissue edema was unaltered by PARP inhibition. Tissue levels of cytokine were only different (P<.05) in PJ34-treated vs untreated mice at 48 hours of reperfusion. Vascular endothelial growth factor levels in PJ34-treated mice were markedly reduced when compared with untreated mice only after 4 hours of reperfusion (P<.01), and in PARP-/- mice (P<.01) at 48 hours of reperfusion. Conclusion: Polyadenosine diphosphate-ribose polymerase modulates skeletal muscle viability, cytokine and vascular endothelial growth factor synthesis during reperfusion. Polyadenosine diphosphate-ribose polymerase inhibition may represent a novel method to modulate skeletal muscle ischemia-reperfusion injury.

UR - http://www.scopus.com/inward/record.url?scp=20144387360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144387360&partnerID=8YFLogxK

U2 - 10.1001/archsurg.140.4.344

DO - 10.1001/archsurg.140.4.344

M3 - Article

VL - 140

SP - 344

EP - 351

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 4

ER -